MEK inhibition can upregulate PD-L1 [18,19], potentially increasing targets for anti-PD(L)1 therapy; however, this may also promote an immunosuppressive environment, thus explaining the lack of synergy in CRC. The gene discussed is MAP2K7; the disease is colorectal carcinoma.